J&J Sets The Pace In Race To $10bn RSV Vaccine Market
80% Efficacy Against Severe Disease In 65+ Group
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.